Get started
Author

Cyrille Ndikumukiza

Observed names: C Ndikumukiza, C. Ndikumukiza
OpenAlex ID: A5058994720
Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States
2023 · Regina Nwamaka Nechi, Amey Rane, et al. · Clinical Therapeutics · 7
Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis
2023 · Amey Rane, Regina Nwamaka Nechi, et al. · Journal of Managed Care & Specialty Pharmacy · 5
PDF
Adoption of RTS, S malaria vaccine for children younger than 5 years in Rwanda: A budget impact analysis
2021 · Cyrille Ndikumukiza, Ismaeel Yunusa, et al. · Exploratory Research in Clinical and Social Pharmacy · 4
PDF
EE342 Evaluation of the Cost-Effectiveness of Dapagliflozin Vs. Empagliflozin for Treating Heart Failure with Reduced Ejection Fraction in the United States
2023 · R. Nechi, A. Rane, et al. · Value in Health
EE219 Cost-Effectiveness of Dapagliflozin Vs. Empagliflozin in Patients with Heart Failure and Preserved Ejection Fraction
2023 · A. Rane, R.N. Nechi, et al. · Value in Health
PDF
Budget Impact Analysis of Malaria Vaccine in Children Younger than 5 Years in Rwanda: A Donor Perspective
2018 · C Ndikumukiza, I Yunusa, et al. · Value in Health
Treatment Strategies in Children with Severe Sickle Cell Disease after the Introduction of L-Glutamine Powder: A Decision Analysis
2018 · I Yunusa, C Ndikumukiza, et al. · Value in Health
Price Analysis Of Oral Antidepressant Drugs With Generic Competition Marketed In The United States (1988-2015)
2016 · J Paredes, C Liu, et al. · Value in Health
Works count: 8
Citation count: 16
H-index: 3
I10-index:
Year
Topic
Type